Symbols / CNSP Stock $5.42 +7.33% CNS Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM
CNSP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Rami Levin M.B.A.
Exch · Country NCM · United States
Market Cap 7.92M
Enterprise Value 5.20M
Income -16.49M
Sales —
FCF (ttm) -8.90M
Book/sh 0.09
Cash/sh 2.02
Employees 4
Insider 10d —
IPO Nov 08, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.00
Forward P/E -13.90
PEG —
P/S —
P/B 62.30
P/C —
EV/EBITDA -0.31
EV/Sales —
Quick Ratio 0.64
Current Ratio 0.89
Debt/Eq 328.62
LT Debt/Eq —
EPS (ttm) -24.12
EPS next Y -0.39
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-05-14
ROA -112.92%
ROE -298.64%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 1.46M
Shs Float 1.29M
Insider Own 0.55%
Instit Own 12.03%
Short Float 4.86%
Short Ratio 1.67
Short Interest 38.97K
52W High 13.92
vs 52W High -61.06%
52W Low 1.90
vs 52W Low 185.26%
Beta —
Impl. Vol. —
Rel Volume 0.02
Avg Volume 1.40M
Volume 23.00K
Target (mean) $10.00
Tgt Median $10.00
Tgt Low $10.00
Tgt High $10.00
# Analysts 1
Recom Buy
Prev Close $5.05
Price $5.42
Change 7.33%
About

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.00
Mean price target
2. Current target
$5.42
Latest analyst target
3. DCF / Fair value
$-109.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.42
Low
$10.00
High
$10.00
Mean
$10.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-12 up Maxim Group Hold → Buy $20
2025-03-25 down Maxim Group Buy → Hold —
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-18 CHARLES FAITH L. Director — 7,100 $4.79 $34,002
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
15.99
+7.28%
14.90
-21.01%
18.87
+23.57%
15.27
Research And Development
9.77
+5.19%
9.29
-34.09%
14.10
+51.56%
9.30
Selling General And Administration
6.21
+10.74%
5.61
+17.66%
4.77
-20.07%
5.97
General And Administrative Expense
6.21
+10.74%
5.61
+17.66%
4.77
-20.07%
5.97
Other Gand A
6.21
+10.74%
5.61
+17.66%
4.77
-20.07%
5.97
Total Expenses
15.99
+7.28%
14.90
-21.01%
18.87
+23.57%
15.27
Operating Income
-15.99
-7.28%
-14.90
+21.01%
-18.87
-23.57%
-15.27
Total Operating Income As Reported
-15.99
-7.28%
-14.90
+21.01%
-18.87
-23.57%
-15.27
EBITDA
-15.83
-6.69%
-14.84
+21.21%
-18.83
-23.45%
-15.26
Normalized EBITDA
-15.83
-6.69%
-14.84
+21.21%
-18.83
-23.45%
-15.26
Reconciled Depreciation
0.00
+18.51%
0.00
-20.03%
0.00
-64.83%
0.01
EBIT
-15.84
-6.70%
-14.84
+21.21%
-18.84
-23.39%
-15.27
Net Income
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Pretax Income
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Net Non Operating Interest Income Expense
0.14
+213.88%
0.04
+217.98%
0.01
+297.55%
-0.01
Interest Expense Non Operating
0.02
-5.52%
0.02
+16.77%
0.01
+96.46%
0.01
Net Interest Income
0.14
+213.88%
0.04
+217.98%
0.01
+297.55%
-0.01
Interest Expense
0.02
-5.52%
0.02
+16.77%
0.01
+96.46%
0.01
Interest Income Non Operating
0.15
+155.19%
0.06
+117.65%
0.03
0.00
Interest Income
0.15
+155.19%
0.06
+117.65%
0.03
0.00
Other Income Expense
-0.00
—
—
—
Other Non Operating Income Expenses
-0.00
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Net Income From Continuing Operation Net Minority Interest
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Net Income From Continuing And Discontinued Operation
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Net Income Continuous Operations
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Normalized Income
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Net Income Common Stockholders
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Diluted EPS
-35.75
+92.34%
-466.89
+99.49%
-91,068.72
+68.40%
-288,191.21
Basic EPS
-35.75
+92.34%
-466.89
+99.49%
-91,068.72
+68.40%
-288,191.21
Basic Average Shares
0.44
+1293.23%
0.03
+15273.43%
0.00
+290.57%
0.00
Diluted Average Shares
0.44
+1293.23%
0.03
+15273.43%
0.00
+290.57%
0.00
Diluted NI Availto Com Stockholders
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
8.62
-0.89%
8.70
+411.56%
1.70
-86.97%
13.05
Current Assets
8.10
-6.42%
8.66
+444.16%
1.59
-87.34%
12.56
Cash Cash Equivalents And Short Term Investments
7.20
+11.45%
6.46
+1077.53%
0.55
-94.54%
10.06
Cash And Cash Equivalents
7.20
+11.45%
6.46
+1077.53%
0.55
-94.54%
10.06
Cash Financial
—
—
0.55
-94.54%
10.06
Receivables
0.00
-100.00%
0.88
0.00
—
Accounts Receivable
0.00
-100.00%
0.88
0.00
—
Prepaid Assets
—
—
—
2.51
Current Deferred Assets
0.05
+120.41%
0.02
-89.83%
0.20
0.00
Other Current Assets
0.86
-33.82%
1.29
+54.12%
0.84
-66.54%
2.51
Total Non Current Assets
0.52
+1126.97%
0.04
-61.31%
0.11
-77.55%
0.49
Net PPE
0.02
+194.80%
0.01
+21.73%
0.00
-12.91%
0.01
Non Current Deferred Assets
—
—
—
0.00
Non Current Prepaid Assets
0.50
+1280.63%
0.04
-65.22%
0.10
-78.30%
0.48
Total Liabilities Net Minority Interest
4.10
+62.46%
2.52
-58.84%
6.13
+24.65%
4.92
Current Liabilities
4.10
+62.46%
2.52
-58.84%
6.13
+24.65%
4.92
Payables And Accrued Expenses
3.77
+71.61%
2.20
-62.31%
5.83
+29.31%
4.51
Payables
—
—
—
3.68
Accounts Payable
—
—
—
3.68
Current Accrued Expenses
—
—
—
0.83
Current Debt And Capital Lease Obligation
0.33
+0.77%
0.33
+8.40%
0.30
-26.63%
0.41
Current Debt
0.33
+0.77%
0.33
+8.40%
0.30
-26.63%
0.41
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
0.00
Stockholders Equity
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Common Stock Equity
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Capital Stock
0.00
+436.44%
0.00
+5800.00%
0.00
-99.88%
0.00
Common Stock
0.00
+436.44%
0.00
+5800.00%
0.00
-99.88%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
0.63
+436.96%
0.12
+56806.28%
0.00
+290.57%
0.00
Ordinary Shares Number
0.63
+436.96%
0.12
+56806.28%
0.00
+290.57%
0.00
Additional Paid In Capital
104.80
+15.67%
90.60
+39.10%
65.13
+10.69%
58.85
Retained Earnings
-100.28
-18.77%
-84.42
-21.36%
-69.57
-37.17%
-50.72
Total Equity Gross Minority Interest
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Total Capitalization
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Working Capital
4.00
-34.76%
6.13
+235.06%
-4.54
-159.41%
7.64
Invested Capital
4.85
-25.40%
6.50
+257.40%
-4.13
-148.36%
8.54
Total Debt
0.33
+0.77%
0.33
+8.40%
0.30
-26.63%
0.41
Net Tangible Assets
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Tangible Book Value
4.52
-26.78%
6.18
+239.36%
-4.43
-154.50%
8.13
Current Notes Payable
0.33
+0.77%
0.33
+8.40%
0.30
-26.63%
0.41
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.81
+19.30%
-17.11
-21.03%
-14.14
-33.93%
-10.56
Cash Flow From Continuing Operating Activities
-13.81
+19.30%
-17.11
-21.03%
-14.14
-33.93%
-10.56
Net Income From Continuing Operations
-15.85
-6.68%
-14.86
+21.18%
-18.85
-23.42%
-15.27
Depreciation Amortization Depletion
0.00
+18.51%
0.00
-20.03%
0.00
-64.83%
0.01
Depreciation
0.00
+18.51%
0.00
-20.03%
0.00
-64.83%
0.01
Depreciation And Amortization
0.00
+18.51%
0.00
-20.03%
0.00
-64.83%
0.01
Other Non Cash Items
—
0.60
—
—
Stock Based Compensation
0.19
-77.62%
0.84
-16.72%
1.01
-16.26%
1.20
Asset Impairment Charge
—
—
0.00
-100.00%
0.33
Operating Gains Losses
0.00
+1446.84%
-0.00
-138.15%
0.00
-83.99%
0.00
Gain Loss On Sale Of PPE
0.00
+1446.84%
-0.00
-138.15%
0.00
-83.99%
0.00
Change In Working Capital
1.85
+149.95%
-3.69
-199.86%
3.70
+16.90%
3.16
Change In Prepaid Assets
0.30
+604.90%
-0.06
-102.52%
2.38
+176.28%
0.86
Change In Payables And Accrued Expense
1.54
+142.45%
-3.63
-374.91%
1.32
-42.62%
2.30
Change In Accrued Expense
—
—
—
0.60
Change In Payable
—
—
—
1.70
Change In Account Payable
—
—
—
1.70
Investing Cash Flow
-0.02
-333.98%
-0.00
-7.36%
-0.00
+11.78%
-0.00
Cash Flow From Continuing Investing Activities
-0.02
-333.98%
-0.00
-7.36%
-0.00
+11.78%
-0.00
Net PPE Purchase And Sale
-0.02
-333.98%
-0.00
-7.36%
-0.00
+11.78%
-0.00
Purchase Of PPE
-0.02
-333.98%
-0.00
-7.36%
-0.00
+11.78%
-0.00
Capital Expenditure
-0.02
-333.98%
-0.00
-7.36%
-0.00
+11.78%
-0.00
Financing Cash Flow
14.57
-36.74%
23.03
+396.63%
4.64
-70.30%
15.61
Cash Flow From Continuing Financing Activities
14.57
-36.74%
23.03
+396.63%
4.64
-70.30%
15.61
Net Issuance Payments Of Debt
-0.30
+1.08%
-0.30
+31.44%
-0.44
-2.58%
-0.43
Repayment Of Debt
-0.30
+1.08%
-0.30
+31.44%
-0.44
-2.58%
-0.43
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Short Term Debt Payments
-0.30
+1.08%
-0.30
+31.44%
-0.44
-2.58%
-0.43
Net Short Term Debt Issuance
-0.30
+1.08%
-0.30
+31.44%
-0.44
-2.58%
-0.43
Net Common Stock Issuance
14.04
-39.92%
23.38
+908.65%
2.32
-85.55%
16.04
Common Stock Payments
-0.00
0.00
—
—
Repurchase Of Capital Stock
-0.00
0.00
—
—
Proceeds From Stock Option Exercised
0.00
-82.99%
0.02
-99.28%
2.96
+108211.59%
0.00
Net Other Financing Charges
0.82
+1326.15%
-0.07
+67.10%
-0.20
—
Changes In Cash
0.74
-87.49%
5.91
+162.19%
-9.51
-288.22%
5.05
Beginning Cash Position
6.46
+1077.53%
0.55
-94.54%
10.06
+100.93%
5.00
End Cash Position
7.20
+11.45%
6.46
+1077.53%
0.55
-94.54%
10.06
Free Cash Flow
-13.83
+19.21%
-17.12
-21.02%
-14.14
-33.91%
-10.56
Interest Paid Supplemental Data
0.02
+12.27%
0.01
-1.49%
0.01
+70.56%
0.01
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
14.05
-39.91%
23.38
+908.65%
2.32
-85.55%
16.04
Issuance Of Capital Stock
14.05
-39.91%
23.38
+908.65%
2.32
-85.55%
16.04
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category